<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HE3902807A9C442BBB37980132D9940AB" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 7828 IH: Price Relief, Innovation, and Competition for Essential Drugs Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-05-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7828</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220518">May 18, 2022</action-date><action-desc><sponsor name-id="S001145">Ms. Schakowsky</sponsor> (for herself, <cosponsor name-id="W000821">Mr. Westerman</cosponsor>, <cosponsor name-id="K000389">Mr. Khanna</cosponsor>, <cosponsor name-id="D000399">Mr. Doggett</cosponsor>, <cosponsor name-id="P000607">Mr. Pocan</cosponsor>, <cosponsor name-id="K000009">Ms. Kaptur</cosponsor>, <cosponsor name-id="G000586">Mr. Garc√≠a of Illinois</cosponsor>, and <cosponsor name-id="D000216">Ms. DeLauro</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.</official-title></form><legis-body id="H019AA697BBA5471B930ED3F18CAA225A" style="OLC"><section id="H67204291BA35429D88EBBF1587403C88" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Price Relief, Innovation, and Competition for Essential Drugs Act</short-title></quote> or the <quote><short-title>PRICED Act</short-title></quote>.</text></section><section id="H6828C3D8AF114FA999809ADF793429D6"><enum>2.</enum><header>Exclusivity period for brand name biological products</header><subsection id="H3F9DDFBCDB854AAC81DB878919EB2989"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 351(k)(7)(A) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)(7)(A)</external-xref>) is amended by striking <quote>12 years</quote> and inserting <quote>5 years</quote>.</text></subsection><subsection id="H9706589C51F0443095490BC5D5DC9020"><enum>(b)</enum><header>Conforming changes</header><text display-inline="yes-display-inline">Paragraphs (2)(A) and (3)(A) of section 351(m) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(m)</external-xref>) is amended by striking <quote>12 years</quote> each place it appears and inserting <quote>5 years</quote>.</text></subsection><subsection id="H5D42FFC8B6784349A07A422BDE2B6ECF"><enum>(c)</enum><header>Applicability</header><text display-inline="yes-display-inline">This Act and the amendments made by this Act apply only with respect to a biological product for which the reference product (as such term is used in section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>)) is licensed under subsection (a) of such section on or after the date of enactment of this Act.</text></subsection></section></legis-body></bill> 

